Imatinib Completed Phase 2 Trials for Metastatic Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00881049Trial of Imatinib (GleevecĀ®) in Selected Patients With Metastatic Melanoma